FDA out­lines a laun­dry list of sur­ro­gate end­points with an eye to ex­pand­ing the ros­ter for drug de­vel­op­ers

The FDA on Wednes­day pub­lished a list of sur­ro­gate end­points to help in­form drug de­vel­op­er dis­cus­sions with rel­e­vant Cen­ter for Bi­o­log­ics Eval­u­a­tion and Re­search (CBER) or Cen­ter for Drug Eval­u­a­tion and Re­search (CDER) re­view di­vi­sions.

The list, which was cre­at­ed thanks to the 21st Cen­tu­ry Cures Act, in­cludes sur­ro­gate end­points that spon­sors have used as pri­ma­ry ef­fi­ca­cy clin­i­cal tri­al end­points for ap­proval of new drug ap­pli­ca­tions (NDAs) or bi­o­log­ics li­cense ap­pli­ca­tions (BLAs). It al­so in­cludes sur­ro­gate end­points that may be ap­pro­pri­ate for use as pri­ma­ry ef­fi­ca­cy clin­i­cal tri­al end­points for drug or bi­o­log­ic ap­provals, al­though they have not yet been used to sup­port an ap­proved NDA or BLA.

The list, which will be up­dat­ed every six months, fea­tures sur­ro­gate end­points for nu­mer­ous dis­eases in­clud­ing acromegaly, dif­fer­ent can­cers, chron­ic kid­ney dis­ease, cys­tic fi­bro­sis, he­pati­tis A, B and C, HIV, hy­per­ten­sion and os­teo­poro­sis, among oth­ers.

“The ac­cept­abil­i­ty of these sur­ro­gate end­points for use in a par­tic­u­lar drug or bi­o­log­ic de­vel­op­ment pro­gram will be de­ter­mined on a case-by-case ba­sis,” the FDA said.

The list, which sep­a­rates adult and pe­di­atric end­points, does not in­clude com­pos­ite end­points that are a com­bi­na­tion of bio­mark­er sur­ro­gate end­points and clin­i­cal end­points. The ta­ble al­so does not in­clude sur­ro­gate end­points that may have been ac­cept­ed for past drug de­vel­op­ment pro­grams but are no longer ac­cept­able as an end­point to sup­port reg­is­tra­tion.

And crit­ics of the list note a lack of speci­fici­ty.

Vinay Prasad

Vinay Prasad, as­so­ciate pro­fes­sor of med­i­cine at Ore­gon Health and Sci­ence Uni­ver­si­ty, told Fo­cus: “I would say, at least for can­cer, it is done at such a high lev­el with so lit­tle de­tail, it is pret­ty much use­less. A bet­ter sum­ma­ry of sur­ro­gates used to jus­ti­fy ap­provals and their strength can be found in our pa­per from the Mayo clin­ic pro­ceed­ings…We are show­ing the sur­ro­gate used by ap­proval, the path­way of ap­proval, and the strength of the sur­ro­gate in the bio­med­ical lit­er­a­ture. They just say what sur­ro­gates are used in what tu­mors, but do not ex­plain the line of ther­a­py, the drugs that uti­lized the path­way or the strength of cor­re­la­tion.”

Back­ground

Ac­cord­ing to sec­tion 507(e)(9) of the Food Drug & Cos­met­ic Act, “[t]he term ‘sur­ro­gate end­point’ means a mark­er, such as a lab­o­ra­to­ry mea­sure­ment, ra­di­ograph­ic im­age, phys­i­cal sign, or oth­er mea­sure, that is not it­self a di­rect mea­sure­ment of clin­i­cal ben­e­fit, and (A) is known to pre­dict clin­i­cal ben­e­fit and could be used to sup­port tra­di­tion­al ap­proval of a drug or bi­o­log­i­cal prod­uct; or (B) is rea­son­ably like­ly to pre­dict clin­i­cal ben­e­fit and could be used to sup­port the ac­cel­er­at­ed ap­proval of a drug or bi­o­log­i­cal prod­uct in ac­cor­dance with sec­tion 506(c).”


First pub­lished here. Reg­u­la­to­ry Fo­cus is the flag­ship on­line pub­li­ca­tion of the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety (RAPS), the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care and re­lat­ed prod­ucts, in­clud­ing med­ical de­vices, phar­ma­ceu­ti­cals, bi­o­log­ics and nu­tri­tion­al prod­ucts. Email news@raps.org for more in­for­ma­tion. 

Author

Zachary Brennan

managing editor, RAPS

Hal Barron and Rick Klausner (GSK, Lyell)

Ex­clu­sive: GSK’s Hal Bar­ron al­lies with Rick Klaus­ner’s $600M cell ther­a­py start­up, look­ing to break new ground blitz­ing sol­id tu­mors

LONDON — Chances are, you’ve heard little or nothing about Rick Klausner’s startup Lyell. But that ends now.

Klausner, the former head of the National Cancer Institute, former executive director for global health at the Gates Foundation, co-founder at Juno and one of the leaders in the booming cell therapy field, has brought together one of the most prominent teams of scientists tackling cell therapy 2.0 — highlighted by a quest to bridge a daunting tech gap that separates some profound advances in blood cancers with solid tumors. And today he’s officially adding Hal Barron and GlaxoSmithKline as a major league collaborator which is pitching in a large portion of the $600 million he’s raised in the past year to make that vision a reality.

“We’ve being staying stealth,” Klausner tells me, then adding with a chuckle: “and going back to stealth after this.”

“Cell therapy has a lot of challenges,” notes Barron, the R&D chief at GSK, ticking off the resistance put up by solid tumors to cell therapies, the vein-to-vein time involved in taking immune cells out of patients, engineering them to attack cancer cells, and getting them back in, and more. “Over the years Rick and I talked about how it would be wonderful to take that on as a mission.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,000+ biopharma pros reading Endpoints daily — and it's free.

First place fin­ish: Eli Lil­ly just moved to fran­chise leader with their sec­ond mi­graine drug OK in 1 year

In a rare twist for Eli Lilly’s historically slow-moving R&D group, the pharma giant has seized bragging rights to a first-in-class new drug approval. And all signs point to an aggressive marketing followup as they look to outclass some major franchise rivals hobbled by internal dissension.

The FDA came through with an OK for lasmiditan on Friday evening, branding it as Reyvow and lining it up — once a substance classification comes through from the DEA — for a major market release. The oral drug binds to 5-HT1F receptors and is designed to stop an acute migraine after it starts. That makes it a complementary therapy to their CGRP drug Emgality, which has a statistically significant impact on preventing attacks.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,000+ biopharma pros reading Endpoints daily — and it's free.

Allogene HQ Open House on September 17, 2019 in South San Francisco. (Jeff Rumans, Endpoints News)

The next 10 years: Where is biotech head­ed?

The last 10 years have seen a revolution in drug development. Timelines have shortened, particularly in oncology. Regulators have opened up. Investment has skyrocketed. China became a player. Biotechs have multiplied as gene and cell therapy has exploded — offering major new advances in the way diseases are treated, and sometimes cured.

So where are we headed from here? I journeyed out to San Francisco in September to discuss the answer to that question at Allogene’s open house. If the last 10 years have been an eye-opener, what does the next decade hold in store?

Patrick Mahaffy, Getty Images

Court green-lights Clo­vis case af­ter de­tail­ing ev­i­dence the board ‘ig­nored red flags’ on false safe­ty and ef­fi­ca­cy da­ta

Clovis investors have cleared a major hurdle in their long-running case against the board of directors, with a Delaware court making a rare finding that they had a strong enough case against the board to proceed with the action.

In a detailed ruling at the beginning of the month that’s been getting careful scrutiny at firms specializing in biotech and corporate governance, the Delaware Court of Chancery found that the attorneys for the investors had made a careful case that the board — a collection of experts that includes high-profile biotech entrepreneurs, a Harvard professor and well-known investigator as well as Clovis CEO Patrick Mahaffy — repeatedly ignored obvious warnings that Mahaffy’s executive crew was touting inflated, unconfirmed data for their big drug Roci. Serious safety issues were also reportedly overlooked while the company continued a fundraising campaign that brought in more than a half-billion dollars. And that leaves the board open to claims related to their role in the fiasco.

The bottom line:

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Bill Gates backs Gink­go Biowork­s' $350M raise to fu­el the buzzy syn­thet­ic bi­ol­o­gy 'rev­o­lu­tion'

If you want to understand Ginkgo Bioworks, the name should suffice: Bioworks, a spin off “ironworks,” that old industrial linchpin devoted to leveraging scale as a wellspring for vast new industries capable of remaking society. Ginkgo wants to be the ironworks for the revolution it’s heralded with as much fanfare as they can, playing off of one of the buzziest technologies in biotech.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,000+ biopharma pros reading Endpoints daily — and it's free.

UCB bags a ri­val to Soliris in $2.1B buy­out deal — but will an in­creas­ing­ly vig­i­lant FTC sign off?

UCB is buying out Ra Pharma $RARX, announcing an acquisition deal that rings up at $48 a share, or $2.1 billion net of cash, and puts them toe-to-toe with Alexion on a clinical showdown.

Ra shares closed at $22.70 on Wednesday.

There’s a small pipeline in play at Ra, but UCB is going for the lead drug — a C5 inhibitor called zilucoplan in Phase III for myasthenia gravis (MG) looking to play rival to Alexion’s Soliris. Soliris has the market advantage, though, with a much earlier approval in MG in late 2017 that UCB feels confident in challenging.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,000+ biopharma pros reading Endpoints daily — and it's free.

A new play­er is tak­ing the field in a push for a he­mo­phil­ia A gene ther­a­py, and it’s a big one

BioMarin, the execs at Spark (and buyer-to-be Roche) as well as the Sangamo/Pfizer team have a new rival striding onto the hemophilia block. And it’s a big one.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,000+ biopharma pros reading Endpoints daily — and it's free.

Stuck with a PhI­II gene ther­a­py fail­ure at 96 weeks, Gen­Sight prefers the up­beat as­sess­ment

Two years after treatment, the best thing that GenSight Biologics $SIGHT can say about their gene therapy for vision-destroying cases of Leber Hereditary Optic Neuropathy is that it’s just a bit better than a placebo — just maybe because one treatment can cover both eyes.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,000+ biopharma pros reading Endpoints daily — and it's free.

George Scangos / Credit: Cornell University

ARCH, Soft­Bank-backed Vir Biotech­nol­o­gy un­der­whelms with $143 mil­lion IPO

George Scangos went back to Wall Street, and came back 700 million pennies short.

Scangos’ vaunted startup Vir Biotechnology raised $143 million in an IPO they hoped would earn $150 million. Shares were priced at $20, the low-end of the $20-$22 target.

Launched with backing from ARCH Venture’s Robert Nelsen, Masayoshi Son’s SoftBank Vision Fund, and the Bill & Melinda Gates Foundation, the infectious disease startup was one of a new wave of well-resourced biotechs that emerged with deep enough coffers to pursue a full R&D line rather than slowly build their case by picking off a single lead program.